Population-based impact of routine infant immunization with pneumococcal conjugate vaccine in the USA.
In the year 2000, a heptavalent pneumococcal conjugate vaccine (PCV7) was licensed and recommended for routine immunization of infants in the USA. During the following years, a number of studies documented the impact of this immunization program on rates of invasive pneumococcal disease, pneumonia and otitis media. This article aims to summarize current evidence on the population-based impact of this infant immunization program in the USA.
Grijalva
Carlos G
CG
Division of Pharmacoepidemiology, Department of Preventive Medicine, Vanderbilt University School of Medicine, 1500 21st Ave S. The Village at Vanderbilt Suite # 2650, Nashville, TN 37212, USA. carlos.grijalva@vanderbilt.edu
Griffin
Marie R
MR
D006801:Humans; D007223:Infant; D010033:Otitis Media / Q000453:epidemiology / Q000517:prevention & control; D011008:Pneumococcal Infections / Q000453:epidemiology / Q000517:prevention & control; D022242:Pneumococcal Vaccines / Q000008:administration & dosage*; D011014:Pneumonia / Q000453:epidemiology / Q000517:prevention & control; D014481:United States / Q000453:epidemiology
D022242:Pneumococcal Vaccines